In the past high costs have been incurred in particular by the market launch of new medicinal
products. To date it was not necessary to demonstrate an additional therapeutic benefit. This
changed with the Act on the Reform of the Market for Medicinal Products (AMNOG) which entered
into force on the 1st of January 2011. It brought about a fundamental change in the balance of
power on the pharmaceutical market. This study therefore sets out to answer the following
question: What impact does the early benefit assessment in the context of the AMNOG have on the
stakeholders of the healthcare system? To answer this question this survey first presents the
theoretical foundations of the law of the early benefit assessment and the bodies involved. It
then takes stock of the decisions taken to date before describing the impact on the selected
stakeholders.
